Abstract Number: 0959 • ACR Convergence 2021
Impact of Systemic Lupus Disease Activity State on Flare Risk After Hydroxychloroquine Maintenance, Reduction or Discontinuation in a Multinational Inception Cohort
Background/Purpose: Physicians and patients often consider reducing or discontinuing hydroxychloroquine (HCQ) among SLE patients in remission or very low disease activity to limit HCQ-induced toxicity.…Abstract Number: 1049 • ACR Convergence 2021
Multimorbidity Differences Between Systemic Lupus Erythematosus Patients and Comparators in Different Age Groups: A Large Nationwide US Study
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) have an increased burden of multimorbidity. Age is strongly associated with accumulation of comorbidities. Patients with SLE may…Abstract Number: 1261 • ACR Convergence 2021
The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus
Background/Purpose: Health-related quality of life (HRQoL) is considered one of the most important outcomes in clinical trials of systemic lupus erythematosus (SLE), along with reduction…Abstract Number: 1277 • ACR Convergence 2021
Patient Perspectives on Two Distinct Patterns of Type 2 SLE Symptoms
Background/Purpose: The Type 1 & 2 SLE Model was developed to better characterize the signs and symptoms of SLE. Type 1 SLE consists of inflammatory…Abstract Number: 1293 • ACR Convergence 2021
Studying Clusters of Patients with SLE According to Cognitive Function, Self-reported Outcomes, Disease Activity, and Clusters Dynamic over 1 Year
Background/Purpose: Systemic Lupus Erythematosus (SLE) has a high prevalence of cognitive impairment (CI) (38% (95% confidence interval: 33-43%)). Patient reported outcomes (PROs) capture patient perceptions…Abstract Number: 1429 • ACR Convergence 2021
ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases
Background/Purpose: B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) are TNF superfamily members that bind TACI (transmembrane activator and CAML interactor), BCMA…Abstract Number: 1486 • ACR Convergence 2021
A Novel Requirement for IFNβ1 Signaling for IFNκ Induction in Keratinocytes
Background/Purpose: Cutaneous lupus erythematosus (CLE) affects up to 70% of patients with systemic lupus erythematosus (SLE), and type I interferons (IFNs) are important promoters of…Abstract Number: 1505 • ACR Convergence 2021
Inflammatory Dendritic Cell and Th17 Polarization in Mouse Model of Lupus Nephritis
Background/Purpose: We have recently identified inflammatory dendritic cells (InfDC) in human lupus kidneys. These cells are over expressed in LN patients compared to healthy controls.…Abstract Number: 1716 • ACR Convergence 2021
Teratogenic Medication Use Associated with Favorable Odds of Contraception Counseling in a Cohort of Women with Systemic Lupus Erythematosus at a Large Tertiary Academic Medical Center
Background/Purpose: Systemic lupus erythematosus (SLE) primarily affects women of childbearing age, who have an increased risk of pregnancy complications such as preterm labor and preeclampsia,…Abstract Number: 1745 • ACR Convergence 2021
Pre-pregnancy Switching from Mycophenolate to Azathioprine in Patients with Lupus Nephritis: A Retrospective Outcome Analysis
Background/Purpose: Mycophenolate Mofetil is not recommended in pregnancy due to teratogenic effects. A previous small prospective study found that switching from MMF to AZA rarely…Abstract Number: 1764 • ACR Convergence 2021
Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients
Background/Purpose: HCQ is an antimalarial drug effective in the treatment of rheumatologic conditions. High blood levels, advanced age, and extended treatment duration are associated with…Abstract Number: 1934 • ACR Convergence 2021
Intra-Individual Change in Cognitive Function Among Adults with Systemic Lupus Erythematosus: A Markov Analysis over 7 Years
Background/Purpose: Cognitive impairment is a prevalent neuropsychiatric manifestation of SLE. Studies have primarily focused on the prevalence of cognitive impairment cross-sectionally; however, there remain gaps…Abstract Number: 0078 • ACR Convergence 2021
Frequency and Clinical Characteristics of Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus: The Georgia Lupus Registry
Background/Purpose: Although APS was originally described in those with SLE, the epidemiology and clinical characteristics of secondary APS (2APS) has not been well described in…Abstract Number: 0324 • ACR Convergence 2021
Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World
Background/Purpose: Around 40-70% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN). LN is often underdiagnosed and early diagnosis is crucial for reducing…Abstract Number: 0340 • ACR Convergence 2021
Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
Background/Purpose: There remains unmet needs of non-invasive markers of disease activity, damage, prognosis, and treatment response in lupus nephritis patients. Here, we aim to validate…
- « Previous Page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- …
- 119
- Next Page »